pfizer
The US pharmaceutical giant Pfizer on Tuesday said its earnings for the second quarter had declined from last year but beat analysts' expectations. The company's earnings came in at $41 million, or $0.01 per share. This compares with $2.327 billion, or $0.41 per share, in last year's second quarter. Excluding items, Pfizer reported adjusted earnings of $3.400 billion or $0.60 per share for the period. Analysts on average had expected the company to earn $0.46 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items. The company's revenue ...
DPA
The US pharmaceutical giant Pfizer on Tuesday said its earnings for the second quarter had declined from last year but beat analysts' expectations. The company's earnings came in at $41 million, or $0.01 per share. This compares with $2.327 billion, or $0.41 per share, in last year's second quarter. Excluding items, Pfizer reported adjusted earnings of $3.400 billion or $0.60 per share for the period. Analysts on average had expected the company to earn $0.46 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items. The company's revenue ...
DPA International
The US pharmaceutical giant Pfizer on Tuesday said its earnings for the second quarter had declined from last year but beat analysts' expectations. The company's earnings came in at $41 million, or $0.01 per share. This compares with $2.327 billion, or $0.41 per share, in last year's second quarter. Excluding items, Pfizer reported adjusted earnings of $3.400 billion or $0.60 per share for the period. Analysts on average had expected the company to earn $0.46 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items. The company's revenue ...
DPA Breaking News
Pfizer Inc (NYSE: PFE) is in focus today after announcing plans of proceeding with a once-a-day formulation of danuglipron – its weight-loss drug. Encouraging data from an ongoing early-stage study informed its decision to move forward with that variant of its obesity pill. Pfizer stock is currently trading slightly below its price at the start of 2024. What’s next for Pfizer Inc in the obesity market?Pfizer tested more than one formulation of its weight-loss drug and picked the one that had “the most favourable profile”. The New York listed firm will conduct trials in the back half of this ye...
Invezz
German drug maker Evotec announced a collaboration with US pharmaceutical company Pfizer to advance drug discovery efforts in France. As per the multi-year master research collaboration and option and license agreement, the companies will initially focus on early discovery research for metabolic and infectious diseases. Evotec, based in Hamburg, noted that the research will be carried out at its sites in France, includingCampus Curie in Toulouse, a state-of-the-art research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics. Evo...
DPA International
German drug maker Evotec announced a collaboration with US pharmaceutical company Pfizer to advance drug discovery efforts in France. As per the multi-year master research collaboration and option and license agreement, the companies will initially focus on early discovery research for metabolic and infectious diseases. Evotec, based in Hamburg, noted that the research will be carried out at its sites in France, includingCampus Curie in Toulouse, a state-of-the-art research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics. Evo...
DPA Breaking News
German drug maker Evotec announced a collaboration with US pharmaceutical company Pfizer to advance drug discovery efforts in France. As per the multi-year master research collaboration and option and license agreement, the companies will initially focus on early discovery research for metabolic and infectious diseases. Evotec, based in Hamburg, noted that the research will be carried out at its sites in France, includingCampus Curie in Toulouse, a state-of-the-art research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics. Evo...
DPA
Washington (AFP) - A Pfizer medicine has been shown to greatly reduce cancer progression and improve survival outcomes for people in the advanced stages of a form of lung cancer, results published Friday showed. Lorlatinib, which is already approved and available under the brand name Lobrena in the United States, was tested in a clinical trial of hundreds of people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Roughly half received lorlatinib while the rest received crizotinib, an earlier generation drug. After five years of follow-up time, more th...
AFP
The letter from the plaintiff's lawyer was addressed to all 27 EU leaders and Manfred Weber, the president of von der Leyen’s European People’s Party (EPP). Its receipt was logged yesterday (29 May) at the European Council. The plaintiff asked EU leaders “to refer the [Pfizergate] matter to the Court of Justice so that it may order the compulsory resignation and forfeiture of pension rights not only of Mrs von der Leyen but also of all the European Commissioners who make up her Commission.” Additionally, the plaintiff asked “the European People's Party to withdraw the candidacy of Ms von der L...
Euronews (English)
New York (United States) (AFP) - Pfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and implements previously announced cost cuts. Much lower sales of Covid-19 vaccine Comirnaty and therapeutic Paxlovid accounted for a 20 percent drop in first-quarter revenues to $14.9 billion compared with the year-ago period. Profits were $3.1 billion, down 44 percent. The drugmaker pointed to increased sales of oncology products, in part driven by the acquisition of Seagen, which was completed in December. Other produ...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら